CLDX
Price:
$25.39
Market Cap:
$1.68B
Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-0159, a Phase I monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity; CDX-1140, a human agonist monoclonal antibody targeted to CD40, a key activator of immune response, which is found on dendritic cells, macrophages, and B cells, as well as is expressed on various cancer cells; and CDX-527, a bispecific antibody, wh...[Read more]
Industry
Biotechnology
IPO Date
1986-05-15
Stock Exchange
NASDAQ
Ticker
CLDX
According to Celldex Therapeutics, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 1.64B. This represents a change of -19.73% compared to the average of 2.05B of the last 4 quarters.
The mean historical Enterprise Value of Celldex Therapeutics, Inc. over the last ten years is 979.77M. The current 1.64B Enterprise Value has changed 16.67% with respect to the historical average. Over the past ten years (40 quarters), CLDX's Enterprise Value was at its highest in in the June 2024 quarter at 2.53B. The Enterprise Value was at its lowest in in the March 2020 quarter at 9.96M.
Average
979.77M
Median
966.50M
Minimum
11.54M
Maximum
2.06B
Discovering the peaks and valleys of Celldex Therapeutics, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 1.83%
Maximum Annual Enterprise Value = 2.06B
Minimum Annual Increase = -96.52%
Minimum Annual Enterprise Value = 11.54M
Year | Enterprise Value | Change |
---|---|---|
2023 | 1.89B | -8.49% |
2022 | 2.06B | 27.40% |
2021 | 1.62B | 238.33% |
2020 | 478.94M | 1.83% |
2019 | 24.78M | 114.66% |
2018 | 11.54M | -96.52% |
2017 | 331.34M | 4.54% |
2016 | 316.95M | -78.20% |
2015 | 1.45B | -9.47% |
2014 | 1.61B | -8.85% |
The current Enterprise Value of Celldex Therapeutics, Inc. (CLDX) is less than than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
1.86B
5-year avg
1.22B
10-year avg
979.77M
Celldex Therapeutics, Inc.’s Enterprise Value is less than IDEAYA Biosciences, Inc. (2.15B), greater than AnaptysBio, Inc. (909.29M), greater than MeiraGTx Holdings plc (448.89M), less than Keros Therapeutics, Inc. (1.86B), greater than Homology Medicines, Inc. (-103303255.00), less than Cerevel Therapeutics Holdings, Inc. (8.24B), less than Avidity Biosciences, Inc. (4.68B), less than Revolution Medicines, Inc. (9.07B), greater than Day One Biopharmaceuticals, Inc. (1.07B), less than SpringWorks Therapeutics, Inc. (2.23B), less than Cytokinetics, Incorporated (6.66B), less than DICE Therapeutics, Inc. (2.21B), less than Edgewise Therapeutics, Inc. (3.19B), less than Karuna Therapeutics, Inc. (12.43B), less than Dyne Therapeutics, Inc. (2.31B), less than Crinetics Pharmaceuticals, Inc. (4.87B), greater than ALX Oncology Holdings Inc. (80.42M), greater than Immatics N.V. (903.76M), greater than BioAtla, Inc. (36.67M), greater than Aerovate Therapeutics, Inc. (48.13M), less than Travere Therapeutics, Inc. (1.78B), greater than Ventyx Biosciences, Inc. (122.28M), greater than Cogent Biosciences, Inc. (1.23B),
Company | Enterprise Value | Market cap |
---|---|---|
2.15B | $2.53B | |
909.29M | $602.18M | |
448.89M | $461.30M | |
1.86B | $2.25B | |
-103303255.00 | $3.02M | |
8.24B | $8.19B | |
4.68B | $5.25B | |
9.07B | $9.33B | |
1.07B | $1.49B | |
2.23B | $2.30B | |
6.66B | $6.06B | |
2.21B | $2.27B | |
3.19B | $3.23B | |
12.43B | $12.60B | |
2.31B | $2.89B | |
4.87B | $5.12B | |
80.42M | $78.48M | |
903.76M | $1.12B | |
36.67M | $96.67M | |
48.13M | $78.52M | |
1.78B | $1.41B | |
122.28M | $151.94M | |
1.23B | $1.30B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Celldex Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Celldex Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is Celldex Therapeutics, Inc.'s Enterprise Value?
What is the highest Enterprise Value for Celldex Therapeutics, Inc. (CLDX)?
What is the 3-year average Enterprise Value for Celldex Therapeutics, Inc. (CLDX)?
What is the 5-year average Enterprise Value for Celldex Therapeutics, Inc. (CLDX)?
How does the current Enterprise Value for Celldex Therapeutics, Inc. (CLDX) compare to its historical average?